Loss of proliferative control and failure to undergo cellular differentiation are key events during carcinogenesis. We recently identified a new potential tumor suppressor gene named MTUS1 (mitochondrial tumor suppressor 1), down−regulated in undifferentiated tumor cell lines, inhibiting tumor cell proliferation after recombinant over−expression. »
01/01/10

It has been reported that fatherhood status may be a risk factor for prostate cancer. In the current study, the authors examined the subsequent occurrence of prostate cancer in a cohort of men evaluated for infertility to determine whether male infertility is a risk factor for prostate cancer. »
03/22/10

Solid tumors contain underperfused regions where hypoxia−inducible factor−1alpha (HIF−1alpha) over−expression induces hypoxia adaptation and cell proliferation. We test the hypothesis that systemic hypoxia promotes prostate cancer growth in vivo and examine HIF−1alpha centrality in this effect. »
03/23/10

This study examined the clinical significance of CCNE1 (Cyclin E1) amplification and assessed whether CCNE1 is a potential therapeutic target in ovarian cancer. »
03/24/10

Lysophosphatidic acid (LPA) is a bioactive lipid crucial for the initiation and progression of ovarian cancer. Identification of LPA−induced biomarkers is necessary for predicting prognosis of ovarian cancer patients. »
03/22/10

Previous studies have observed an association between ABO blood group and risk of certain malignancies, including ovarian cancer; however, no prospective studies of the association with ovarian cancer risk are available. »
03/22/10

In the current study, we investigated the mechanism relating down−regulation of MKK4 expression to development of ovarian cancer. »
03/22/10

Snail, a key inducer of epithelial−mesenchymal transition (EMT), plays an important role in cancer metastasis. »
03/01/10

Because folate receptor alpha (FRalpha) is frequently over−expressed in epithelial ovarian tumors, we hypothesized that its association with folate may differ by FRalpha expression or by the timing of intake. »
03/01/10

Tyroservatide (YSV) is an active, low−molecular−weight polypeptide shown to have anti−tumor effects on experimental hepatocarcinoma and lung carcinoma. »
03/22/10